Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with the historical ticker IKNA document the regulatory and corporate path of Ikena Oncology, Inc. as it transitioned into neBio, Inc. and shifted its Nasdaq listing to the ticker IMA. These filings include multiple Forms 8-K that describe material events such as the execution and completion of the merger with Inmagene Biopharmaceuticals, the 1-for-12 reverse stock split of Ikena common stock, and the formal change of the corporate name from Ikena Oncology, Inc. to neBio, Inc.
Within these documents, investors can find detailed descriptions of the Agreement and Plan of Merger, the two-step merger structure that made Inmagene a wholly owned subsidiary, and the resulting ownership structure of the combined company. Other filings outline the approval and implementation of new equity incentive and employee stock purchase plans that become effective after the merger, as well as the creation of contingent value rights agreements for Ikena’s legacy assets, including IK-595, and certain Inmagene assets other than -007.
Additional 8-K filings cover corporate actions such as the adoption of a 2025 Inducement Plan, the dismissal of Ernst & Young LLP as the independent registered public accounting firm and the engagement of PricewaterhouseCoopers LLP, and the mechanics and timing of the reverse stock split and new listing details on The Nasdaq Capital Market under IMA. Earlier filings and periodic reports referenced in these documents provide context on Ikena’s targeted oncology programs, including IK-930 and IK-595, and its completed collaboration with Bristol-Myers Squibb.
On Stock Titan’s filings page, users can access these SEC documents in one place and use AI-powered tools to surface key elements such as merger terms, reverse split ratios, contingent value rights mechanics, and changes in auditors or compensation plans. This helps readers quickly understand how Ikena’s historical IKNA listing evolved into neBio, Inc.’s current IMA listing and how legacy oncology and inflammatory disease assets are treated in the company’s regulatory record.
Ikena Oncology filed an 8-K announcing a 1-for-12 reverse stock split of its common stock, effective at the start of trading on 28 Jul 2025. Every 12 pre-split shares will convert into 1 post-split share; fractional shares will be paid out in cash based on Nasdaq’s 24 Jul 2025 closing price. The split will reduce outstanding shares from approximately 48.2 million to roughly 4 million, while authorised share capital and the $0.001 par value remain unchanged; exercise prices and share counts under outstanding equity awards will be adjusted proportionately.
At the same time the company will rebrand as ImageneBio, Inc., adopt the new ticker IMA, and switch CUSIP to 45175G207, continuing to trade on the Nasdaq Capital Market. Computershare is serving as exchange agent, and shareholders whose holdings are in book-entry or brokerage accounts need not take any action.
The filing is limited to corporate-action details and a comprehensive forward-looking-statement section that highlights risks surrounding the planned merger with Inmagene Biopharmaceuticals, the concurrent financing, and completion of the reverse split. No financial performance metrics were provided.